We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Celgene Amends Complaint In Thalomid Spat

Law360 (October 3, 2007, 12:00 AM EDT) -- Pharmaceutical company Celgene Corp. has launched another attack in its ongoing crusade to protect cancer drug Thalomid from generic competition, filing an amended complaint in the pending patent litigation against generic maker Barr Laboratories.

Filed on Tuesday in the U.S. District Court for the District of New Jersey, the complaint reasserts allegations that Barr's proposed generic version of Thalomid would violate eight of Celgene's patents for the drug.

The amended complaint adds a newly granted patent to the suit, which is also the subject of a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.